Welcome to our dedicated page for DBV Technologies S.A. SEC filings (Ticker: DBVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DBV Technologies S.A. filings document the disclosure record of a French late-stage biopharmaceutical issuer with American Depositary Shares listed under DBVT. The filings identify ordinary shares and ADSs, with each ADS representing five ordinary shares, and cover the company’s VIASKIN patch technology, epicutaneous immunotherapy approach, and food-allergy development programs.
Recent SEC materials include Form 8-K reports for operating results, business highlights, clinical-data releases for the Phase 3 VITESSE study, warrant-related financing events, and governance matters. Proxy materials describe shareholder meeting proposals, board and committee matters, executive compensation, and equity-award plans.
DBV Technologies S.A. (DBVT) reported an equity award to its Chief Commercial Officer on a Form 4 insider filing. On November 21, 2025, the officer received 55,000 ordinary shares through a restricted stock unit (RSU) award and 316,250 employee stock options with an exercise price of $2.9 per share. Both the RSUs and options vest in four equal annual installments starting on November 21, 2026, contingent on continued service. The options expire on November 21, 2035. The ordinary shares may be represented by American Depositary Shares, with each ADS currently representing five ordinary shares.
DBV Technologies S.A. (DBVT) reported a Form 4 insider transaction for its Chief Executive Officer and director. On 11/21/2025, the reporting person received an employee stock option grant to buy 964,000 ordinary shares of DBV Technologies.
The option has an exercise price of $2.9 per share, stated in U.S. dollars and based on converting euros at an exchange rate of $1.15154 to €1.00 as of November 21, 2025. These options are exercisable until 11/21/2035 and were fully reported as directly owned.
The option vests in four equal annual installments starting on November 21, 2026, as long as the executive continues to provide service through each vesting date. This filing reflects an equity-based compensation award rather than an open-market purchase or sale of shares.
DBV Technologies S.A. (DBVT) reported an insider ownership update via Form 3. The reporting person, who serves as Chief Commercial Officer, filed as a single reporting person and stated no securities are beneficially owned. The event date is 11/03/2025. This filing establishes the officer’s initial ownership position, indicating no non-derivative or derivative holdings at the time referenced.
DBV Technologies appointed Philina Lee, Ph.D., to its Board of Directors effective October 30, 2025, filling the vacancy created by the resignation of Daniel Soland. She will also join the Compensation Committee in his place, with her appointment to be submitted to a shareholder vote at the next annual Ordinary and Extraordinary General Meeting.
Lee brings senior commercial and portfolio leadership experience from Blueprint Medicines, Sanofi, Genzyme and Algeta, and prior board service at Fusion Pharmaceuticals. Under the company’s non-employee director compensation policy, she will receive a fixed annual retainer of €100,000 and €5,000 per year for Compensation Committee service.
DBV Technologies S.A. (DBVT) furnished an 8‑K announcing a press release with financial results and business highlights for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1. The information under Item 2.02 is being furnished, not filed, and is not subject to Section 18 liability, nor incorporated by reference except as expressly set forth.
DBV Technologies (DBVT) reported Q3 results and liquidity updates. Cash and cash equivalents were $69.8 million as of September 30, 2025. The company posted a Q3 net loss of $33.2 million and a nine‑month net loss of $102.1 million, driven mainly by R&D spending for the Viaskin Peanut program.
DBV closed a $125.5 million financing in April 2025 and established an ATM program of up to $150.0 million; after quarter‑end it sold 2,307,692 ADSs for gross proceeds of about $30 million on October 6, 2025. The company estimates its cash runway extends into the third quarter of 2026, yet it states these conditions raise substantial doubt about its ability to continue as a going concern. Operating cash use was $86.0 million for the first nine months; financing cash inflows were $117.1 million.
Clinical and regulatory milestones remain central: VITESSE Phase 3 topline results in children 4–7 are anticipated in the fourth quarter of 2025, and up to $181.4 million in additional gross proceeds may be received if warrants are exercised, subject to conditions. As of October 27, 2025, 169,113,619 ordinary shares were outstanding including treasury shares.
DBV Technologies S.A. reported that Daniel Soland has resigned from its Board of Directors and from the Board’s compensation committee, effective September 18, 2025. The company states that his resignation was not due to any dispute or disagreement with the company or the Board, indicating an orderly departure rather than a conflict-driven exit.
DBV Technologies also issued a press release on September 18, 2025 to announce this Board change, which is included as an exhibit to this report for additional background on the transition.
DBV Technologies S.A. filed an 8-K reporting a set of corporate filings and agreements dated September 5, 2025. The filing references a S-3 registration statement No. 333-271166 and a Sales Agreement between DBV and Citizens JMP Securities, LLC executed on September 5, 2025. Legal opinion and consent from Gide Loyrette Nouel A.A.R.P.I. are included (Exhibit 5.1), and a company press release dated September 5, 2025 is furnished. The document includes an interactive Inline XBRL cover page and is signed by Virginie Boucinha, Chief Financial Officer.
The filing is procedural and confirms registration and an at-the-market style sales agreement that could enable securities offers under the S-3 shelf; however, the 8-K does not disclose offering size, pricing, or timing.
DBV Technologies is pursuing regulatory approval for its Viaskin Peanut patch and has progressed with U.S. FDA interactions and clinical work. The company resubmitted a Biologics License Application for Viaskin Peanut and reached alignment with the FDA on an Accelerated Approval pathway for toddlers aged 1-3, including key COMFORT Toddlers study design elements and statistical criteria mirroring prior EPITOPE standards (success defined as lower bound of the 95% CI > 15%). On June 25, 2025 the first subject was screened in the COMFORT Toddlers supplemental safety study. The prospectus supplement also discloses tax and corporate governance considerations, including PFIC risk, ADS listing on Nasdaq under "DBVT", and historical ADS and Euronext Paris prices.
Venrock-affiliated funds and related entities collectively report beneficial ownership of 14,286,553 ADSs of DBV Technologies S.A., representing 9.8% of the class as of June 30, 2025. The filing aggregates direct ADS holdings and pre-funded warrants exercisable for 9,150,000 Ordinary Shares. The percent calculation uses 136,948,872 Ordinary Shares outstanding plus the 9,150,000 issuable on exercise of the pre-funded warrants. Multiple Venrock vehicles and two individual reporting persons (Nimish Shah and Bong Y. Koh) are members of the reporting group; managing entities (VHCP Management II/III/EG) serve as general partners or managers for the funds. Signatures and powers of attorney are included by reference.